# Crown Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crown-bioscience

- Industry: Pharmaceuticals
- Headquarters: Santa Clara, US
- Website: www.crownbio.com
- Total disclosed funding: $77M
- Latest round: Series D (May 25, 2014)
- Investors on record: 13

## About

Crown Bioscience, Inc. is a specialized Contract Research Organization (CRO) that focuses on oncology and immuno-oncology drug discovery, offering extensive preclinical and translational services to support pharmaceutical and biotech companies.Founded in 2006 and headquartered in Santa Clara, US, Crown Bioscience operates in the oncology field, providing crucial research services. The company has successfully raised a total of USD 26.55 mn, with its latest fundraising, a Series D round, taking place on May 25, 2014, led by Lilly Asia Ventures. CEO Armin Spura oversees the operations of the firm, which has engaged in seven notable deals since its inception.Crown Bioscience is a Contract Research Organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. The company provides a comprehensive suite of preclinical and translational services aimed at supporting biotech and pharmaceutical companies throughout their research and development processes. Its key offerings include innovative in vitro and in vivo models, particularly for hematological malignancies, utilizing their advanced 3D bone marrow niche models. Tailored methodologies ensure alignment with evolving regulatory frameworks, serving a global clientele that includes major pharmaceutical and biotechnology firms across North America, Europe, and Asia.Crown Bioscience generates revenue primarily through service contracts with pharmaceutical and biotechnology clients, structured as B2B transactions. Their business model includes fixed-price contracts, milestone payments, and retainer fees for ongoing research services. Their flagship offerings, including advanced organoid models and preclinical testing services, drive substantial revenue, reflecting a tailored approach to meet specific client needs. Collaborations and partnerships, such as recent extensions with NEXT Oncology, further support the company’s financial stability and growth. Additionally, they engage clients through on-demand webinars, white papers, and consulting services that enhance client engagement and satisfaction.Crown Bioscience aims to leverage the recent USD 26.55 mn raised in May 2014 to enhance its service offerings and expand into new global markets. Specific strategies include the development of upcoming products designed to improve drug discovery processes, with targeted efforts to broaden their presence in Asia by 2025. The funding will facilitate the launch of these initiatives and support ongoing research, ultimately aiming to enhance patient outcomes through advanced therapeutic solutions.

## Funding rounds

- Series D, May 25, 2014, $27M — Lilly Asia Ventures
- Series C, Jul 24, 2013, $1.7M — Qiming Venture Partners, Argonaut Private Equity
- Series C, Apr 18, 2011, $28M — OrbiMed Advisors, Qiming Venture Partners, Argonaut Private Capital, O-Bank, CDIB Capital Group, China Renaissance Capital Investment, CID Group
- Series B, Jul 17, 2008, $1.6M — Ignition Partners, Qiming Venture Partners, Harbinger Venture Capital, Acorn Campus Ventures
- Series B, Mar 28, 2008, $16M — Ignition Partners, Qiming Venture Partners, Harbinger Venture Capital, Chemizon Inc., Acorn Campus Ventures
- Series A, Apr 20, 2007, $3.1M — Acorn Campus Ventures

## Investors

- Acorn Campus Ventures (https://capitalatlas.ai/funds/acorn-campus-ventures) — Series A, Series B
- Ignition Partners (https://capitalatlas.ai/funds/ignition-partners) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C
- Harbinger Venture Capital (https://capitalatlas.ai/funds/harbinger-venture-capital) — Series B
- Chemizon Inc. — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Argonaut Private Capital — Series C
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series C
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- China Renaissance Capital Investment (https://capitalatlas.ai/funds/china-renaissance-capital-investment) — Series C
- CID Group (https://capitalatlas.ai/funds/cid-group) — Series C
- Argonaut Private Equity (https://capitalatlas.ai/funds/argonaut-private-equity) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series D